目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Cancer Stem Cells Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Cancer Stem Cells Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Cancer Stem Cells Market: Mode of Action Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Cancer Stem Cells Market: Mode of Action Movement Analysis, 2023 & 2030 (USD Million)
4.3. Targeted Cancerous Stem Cells (CSCs)
4.3.1. Targeted Cancerous Stem Cells (CSCs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Pathway Inhibitors
4.3.2.1. Pathway Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.2. WNT Signaling Pathway
4.3.2.2.1. WNT Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.3. Hedgehog Signaling Pathway
4.3.2.3.1. Hedgehog Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.4. Notch Signaling Pathway
4.3.2.4.1. Notch Signaling Pathway Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2.5. Others
4.3.2.5.1. Other Signaling Pathways Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Surface Marker-based
4.3.3.1. Surface Marker-based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Immuno-evasion & Targeting Tumor Microenvironment
4.3.4.1. Immuno-evasion & Targeting Tumor Microenvironment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.5. Nanoparticle-based Therapies
4.3.5.1. Nanoparticle-based Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.6. Others
4.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7. By Products
4.3.7.1. By Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7.2. Cell-Culturing
4.3.7.2.1. Cell-Culturing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7.3. Cell-Separation
4.3.7.3.1. Cell-Separation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7.4. Cell Analysis
4.3.7.4.1. Cell Analysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7.5. Molecular Analysis
4.3.7.5.1. Molecular Analysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.7.6. Others
4.3.7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Stem Cell Usage Against Cancer
4.4.1. Stem Cell Against Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Autologous SC Transplant
4.4.2.1. Autologous SC Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Allogeneic SC Transplant
4.4.3.1. Allogeneic SC Transplant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Stem Cells Market: Cancer Forms Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Cancer Stem Cells Market: Cancer Forms Movement Analysis, 2023 & 2030 (USD Million)
5.3. Breast
5.3.1. Breast Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Blood
5.4.1. Blood Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Lung
5.5.1. Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Brain
5.6.1. Brain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Colorectal
5.7.1. Colorectal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Pancreatic
5.8.1. Pancreatic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Bladder
5.9.1. Bladder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.10. Liver
5.10.1. Liver Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.11. Others
5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Stem Cells Market: Regional Estimates & Trend Analysis
6.1. Cancer Stem Cells Market Share, By Region, 2023 & 2030 (USD Million, Kilo Tons)
6.2. North America
6.2.1. North America Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. U.S. Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Canada Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Mexico Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. UK Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Germany Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. France Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Italy Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Spain Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Denmark Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Sweden Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Norway Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. China
6.4.2.1. China Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Japan Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. India Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. South Korea Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Australia Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Thailand Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Argentina Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. UAE Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Kuwait Cancer Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. Thermo Fisher Scientific Inc.
7.4.1.1. Participant’s Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Recent Developments/ Strategic Initiatives
7.4.2. AbbeVie, Inc.
7.4.2.1. Participant’s Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Recent Developments/ Strategic Initiatives
7.4.3. Merck KCaA
7.4.3.1. Participant’s Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Recent Developments/ Strategic Initiatives
7.4.4. Bionomics
7.4.4.1. Participant’s Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Recent Developments/ Strategic Initiatives
7.4.5. Lonza
7.4.5.1. Participant’s Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Recent Developments/ Strategic Initiatives
7.4.6. The Menarini Group
7.4.6.1. Participant’s Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Recent Developments/ Strategic Initiatives
7.4.7. Miltenyi Biotec
7.4.7.1. Participant’s Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Recent Developments/ Strategic Initiatives
7.4.8. PromoCell GmbH
7.4.8.1. Participant’s Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Recent Developments/ Strategic Initiatives
7.4.9. MacroGenics, Inc.
7.4.9.1. Participant’s Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Recent Developments/ Strategic Initiatives
7.4.10. OncoMed Pharmaceuticals, Inc.
7.4.10.1. Participant’s Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Recent Developments/ Strategic Initiatives
7.4.11. FUJIFILM Irvine Scientific
7.4.11.1. Participant’s Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Recent Developments/ Strategic Initiatives
7.4.12. STEMCELL Technologies.
7.4.12.1. Participant’s Overview
7.4.12.2. Financial Performance
7.4.12.3. Product Benchmarking
7.4.12.4. Recent Developments/ Strategic Initiatives
7.4.13. Sino Biological, Inc.
7.4.13.1. Participant’s Overview
7.4.13.2. Financial Performance
7.4.13.3. Product Benchmarking
7.4.13.4. Recent Developments/ Strategic Initiatives
7.4.14. Lineage Cell Therapeutics
7.4.14.1. Participant’s Overview
7.4.14.2. Financial Performance
7.4.14.3. Product Benchmarking
7.4.14.4. Recent Developments/ Strategic Initiatives